In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.

ABSTRACT:

Objectives

Doravirine is a recently licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and safety profile compared with efavirenz and limited cross-resistance with rilpivirine and etravirine. In this in vitro study, cross-resistance to doravirine was analysed in a representative panel of NNRTI-resistant clones.

Methods

In vitro phenotypic susceptibility to doravirine was assessed in 10 clinically derived infectious clones with intermediate- to high-level resistance to rilpivirine, etravirine, efavirenz and nevirapine, and in NL4-3 site-directed mutants harbouring K103N, Y181C, M230L or K103N/Y181C NNRTI mutations.

Results

Although none of the infectious clones harboured any of the major doravirine resistance-associated mutations (RAMs) included in the IAS-U

SUBMITTER: Saladini F 

PROVIDER: S-EPMC8453390 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature